Our Humanitarian Efforts and Response to the Crisis in Ukraine
At Pfizer we, like many around the world, are deeply concerned by the human suffering we all are witnessing during the ongoing war in Ukraine. We stand with the unified global community across the public, private, and civil society sectors in opposition of the Russian treatment of the people of Ukraine and are committed to contributing to ongoing humanitarian efforts and to ensuring the safety of our colleagues and their families. We are equally determined to facilitate continued access to our medicines and vaccines for patients and have made significant progress to this end, activating several humanitarian efforts and we continue to expand our support.
To date, we have committed to donating $30 million through The Pfizer Foundation* to causes supporting the Ukrainian people. This includes grants derived from Pfizer’s decision to halt its investments in Russia and donate the equivalent of profits from our Russian subsidiary to causes that provide direct humanitarian support to the people of Ukraine.
The Foundation has approved grants for 12 non-governmental organizations (NGOs), including six local organizations in Poland and Ukraine, to support humanitarian relief and response efforts. This includes food security and support services, shelter, education for children, and other pressing needs of the people of Ukraine.
Through The Pfizer Foundation, we have also launched the Ukraine Humanitarian Disaster Campaign matching financial donations already made by thousands of Pfizer colleagues around the world to support organizations. Including The Pfizer Foundation’s dollar-for-dollar match, the total donation is U.S. $1.86 million.
Pfizer is also responding to the immediate need for access to life-saving medicines through targeted product donations to Ukraine and organizations supporting the Ukrainian people including over 1 million doses of Pfizer products to help healthcare providers and relief workers treat patients in Ukraine and neighboring countries.
In partnership with the U.S. Government and USAID, almost 2 million donated doses of the Pfizer/BioNTech COVID–19 vaccine have now reached Ukraine and we are one of the largest donors to Direct Relief. We have also delivered nearly 200,000 courses of PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets).
“Direct Relief is deeply grateful to Pfizer for its leadership and commitment reflected in this donation for the people of Ukraine. Pfizer’s support is a wonderful example of what’s needed to address this unfolding humanitarian crisis—an infusion of much needed health essentials for the millions of families who have had their lives upended while the health system they rely on has been severely damaged and made them much more vulnerable and facing an uncertain future," said Thomas Tighe, Direct Relief President and CEO.
Pfizer Ukraine Country Manager:
“It is hard to express in words just how proud I am of my team here in Ukraine, who have shown unbelievable resilience and an unwavering dedication to putting patients first, even during the most challenging time in Pfizer Ukraine’s history. But we have not been alone; there have been countless colleagues from the surrounding countries and all around the world who have supported my team and my country. From so many donating to The Pfizer Foundation’s Ukraine Humanitarian Disaster Campaign—which thanks to matching financial donations has raised almost $2 million—or colleagues in neighbouring countries offering to support displaced individuals, through to whole cross-functional teams working round clock to support and protect colleagues on the ground and ensure the continued supply of medicines. This show of unity and commitment to people and patients has been so critical. During the pandemic, I thought I could not be more proud to work for Pfizer—but the company’s support during this time makes me even more proud. The millions of product donations arranged and the $30 million of humanitarian support committed by the Pfizer Foundation has and will continue to, quite literally, save lives,” said Zoriana Tsilyk, Ukraine Country Manager, Pfizer.
PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of adults and pediatric patients (12 years of age and older weighing at least 40 kg) with a current diagnosis of mild-to-moderate COVID-19 and who are at high risk for progression to severe COVID-19, including hospitalization or death.
The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.
* The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc. with distinct legal restrictions.